Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis
出版年份 2020 全文链接
标题
Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis
作者
关键词
-
出版物
Cancers
Volume 12, Issue 8, Pages 2278
出版商
MDPI AG
发表日期
2020-08-14
DOI
10.3390/cancers12082278
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Updated Results from the German Mpnsg-0212 Combination Trial: Ruxolitinib Plus Pomalidomide in Myelofibrosis with Anemia
- (2020) Frank Stegelmann et al. BLOOD
- Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience
- (2020) Elena Maria Elli et al. BLOOD
- Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis
- (2020) Claire N Harrison et al. BLOOD
- A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia
- (2020) Aaron T. Gerds et al. BLOOD
- A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia
- (2020) Prithviraj Bose et al. LEUKEMIA
- Single-cell analysis based dissection of clonality in myelofibrosis
- (2020) Elena Mylonas et al. Nature Communications
- Smad2/3‐pathway ligand trap luspatercept enhances erythroid differentiation in murine β‐thalassaemia by increasing GATA‐1 availability
- (2020) Pedro A. Martinez et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Role of DNA Damage Response in Suppressing Malignant Progression of Chronic Myeloid Leukemia and Polycythemia Vera: Impact of Different Oncogenes
- (2020) Jan Stetka et al. Cancers
- PRMT5 inhibition modulates E2F1 methylation and gene regulatory networks leading to therapeutic efficacy in JAK2V617F mutant MPN
- (2020) Friederike Pastore et al. Cancer Discovery
- Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy
- (2020) Flávia Alves Verza et al. Cancers
- Luspatercept for the treatment of anemia in myelodysplastic syndromes (MDS) and primary myelofibrosis (PMF)
- (2019) Pierre Fenaux et al. BLOOD
- A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis
- (2019) Prithviraj Bose et al. LEUKEMIA & LYMPHOMA
- Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling
- (2019) Daniel A. C. Fisher et al. LEUKEMIA
- Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms
- (2019) Simona Stivala et al. JOURNAL OF CLINICAL INVESTIGATION
- Aurora kinase A inhibition provides clinical benefit, normalizes megakaryocytes and reduces bone marrow fibrosis in patients with myelofibrosis
- (2019) Naseema Gangat et al. CLINICAL CANCER RESEARCH
- Results from HARMONY: an open-label, multicentre, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis
- (2019) Simon T. Durrant et al. HAEMATOLOGICA
- LOXL2—A New Target in Antifibrogenic Therapy?
- (2019) Angela Puente et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis
- (2019) Novella Pugliese et al. Cancer Medicine
- Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis
- (2019) Massimo Breccia et al. ANNALS OF HEMATOLOGY
- Oral Idasanutlin in Patients with Polycythemia Vera
- (2019) John Mascarenhas et al. BLOOD
- Activation of JAK/STAT signaling in megakaryocytes sustains myeloproliferation in vivo
- (2019) Brittany Woods et al. CLINICAL CANCER RESEARCH
- Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms
- (2019) Xing Hao et al. INVESTIGATIONAL NEW DRUGS
- Combination Treatment with Imetelstat, a Telomerase Inhibitor, and Ruxolitinib Depletes Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells
- (2019) Cing Siang Hu et al. BLOOD
- HDAC11 Deficiency or Inhibition Disrupts Oncogene-Induced Stress Hematopoiesis in Myeloproliferative Neoplasms
- (2019) Lanzhu Yue et al. BLOOD
- Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study
- (2019) Raajit K. Rampal et al. BLOOD
- RMC-4550, an Allosteric Inhibitor of SHP2, Displays Therapeutic Efficacy in Pre-Clinical Models of Myeloproliferative Neoplasms
- (2019) Garima Pandey et al. BLOOD
- Prognostic impact of RAS-pathway mutations in patients with myelofibrosis
- (2019) Fabio P. S. Santos et al. LEUKEMIA
- Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations
- (2019) Rebecca J. Austin et al. LEUKEMIA
- LSD1/KDM1A, a Gate-Keeper of Cancer Stemness and a Promising Therapeutic Target
- (2019) Panagiotis Karakaidos et al. Cancers
- Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib
- (2019) Elena Maria Elli et al. Frontiers in Oncology
- Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study.
- (2019) Anders Lindholm Sørensen et al. HAEMATOLOGICA
- A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF)
- (2019) J. Mascarenhas et al. LEUKEMIA RESEARCH
- Glycogen Synthase Kinase-3β Inhibition with 9-ING-41 Attenuates the Progression of Pulmonary Fibrosis
- (2019) Ann Jeffers et al. Scientific Reports
- The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib
- (2018) Elena Crisà et al. BRITISH JOURNAL OF HAEMATOLOGY
- Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms
- (2018) Maria Kleppe et al. CANCER CELL
- Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients
- (2018) Nicola Polverelli et al. HEMATOLOGICAL ONCOLOGY
- Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
- (2018) Hans Michael Kvasnicka et al. Journal of Hematology & Oncology
- JAK2V617F Megakaryocytes Promote Hematopoietic Stem/Progenitor Cell Expansion in Mice through Thrombopoietin/MPL signaling
- (2018) Yu Zhang et al. STEM CELLS
- Mechanisms for mTORC1 activation and synergistic induction of apoptosis by ruxolitinib and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing leukemic cells including newly established PVTL-2
- (2018) Shinya Ishida et al. Oncotarget
- Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management
- (2018) Ayalew Tefferi AMERICAN JOURNAL OF HEMATOLOGY
- A phase II study of ruxolitinib in combination with azacytidine in patients with myelofibrosis
- (2018) Lucia Masarova et al. BLOOD
- A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis
- (2018) Stephen Couban et al. Journal of Hematology & Oncology
- Perspectives on interferon-alpha in the treatment of Polycythemia vera and related Myeloproliferative neoplasms: minimal residual disease and cure?
- (2018) Hans Carl Hasselbalch et al. Seminars in Immunopathology
- Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients
- (2018) Francesca Palandri et al. LEUKEMIA RESEARCH
- Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
- (2017) Srdan Verstovsek et al. Journal of Hematology & Oncology
- Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
- (2017) Srdan Verstovsek et al. Journal of Hematology & Oncology
- Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells
- (2017) D T Saenz et al. LEUKEMIA
- Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis
- (2017) K. Gowin et al. LEUKEMIA RESEARCH
- Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics
- (2017) Stuart W. Ember et al. MOLECULAR CANCER THERAPEUTICS
- Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera
- (2017) T Tsuruta-Kishino et al. ONCOGENE
- How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes
- (2017) Fulvio Massaro et al. Expert Review of Hematology
- BET Proteins as Targets for Anticancer Treatment
- (2017) Anastasios Stathis et al. Cancer Discovery
- Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/ CIP2A axis
- (2017) Niccolò Bartalucci et al. Oncotarget
- Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis
- (2017) Francesca Palandri et al. Oncotarget
- The combination treatment regimen of ruxolitinib with low-dose mercaptopurine or cytarabine in frail patients with blast-phase myelofibrosis
- (2016) Mikhail Fominykh et al. BRITISH JOURNAL OF HAEMATOLOGY
- Preclinical rationale for TGF-β inhibition as a therapeutic target for the treatment of myelofibrosis
- (2016) Ilaria Ceglia et al. EXPERIMENTAL HEMATOLOGY
- A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
- (2016) Vikas Gupta et al. HAEMATOLOGICA
- Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
- (2016) John O. Mascarenhas et al. HAEMATOLOGICA
- Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis
- (2016) Srdan Verstovsek et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence
- (2016) A Tefferi et al. LEUKEMIA
- BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells
- (2016) D T Saenz et al. LEUKEMIA
- JAK2V617F allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy
- (2016) G Barosi et al. LEUKEMIA
- JAK2V617F-mutant megakaryocytes contribute to hematopoietic stem/progenitor cell expansion in a model of murine myeloproliferation
- (2016) H Zhan et al. LEUKEMIA
- Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia
- (2016) D A C Fisher et al. LEUKEMIA
- Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
- (2016) C N Harrison et al. LEUKEMIA
- A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
- (2016) Vikas Gupta et al. HAEMATOLOGICA
- Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
- (2016) John O. Mascarenhas et al. HAEMATOLOGICA
- Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results
- (2015) Francisco Cervantes et al. ANNALS OF HEMATOLOGY
- Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib
- (2015) K. P. Patel et al. BLOOD
- The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis
- (2015) M. Deininger et al. BLOOD
- Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms
- (2015) Raynier Devillier et al. BRITISH JOURNAL OF HAEMATOLOGY
- The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond
- (2015) Nicole Stopa et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I
- (2015) Ruben A. Mesa et al. Clinical Lymphoma Myeloma & Leukemia
- Ruxolitinib in combination with Lenalidomide as therapy for patients with myelofibrosis
- (2015) N. Daver et al. HAEMATOLOGICA
- A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
- (2015) A. M. Vannucchi et al. HAEMATOLOGICA
- Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
- (2015) S. Verstovsek et al. HAEMATOLOGICA
- Megakaryocytic hyperplasia in myeloproliferative neoplasms is driven by disordered proliferative, apoptotic and epigenetic mechanisms
- (2015) Jacques A J Malherbe et al. JOURNAL OF CLINICAL PATHOLOGY
- Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis
- (2015) Catriona Jamieson et al. Journal of Translational Medicine
- Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis
- (2015) S Verstovsek et al. LEUKEMIA
- Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition
- (2015) Qiang Jeremy Wen et al. NATURE MEDICINE
- A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis
- (2015) Ayalew Tefferi et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis
- (2015) A Pardanani et al. Blood Cancer Journal
- The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells
- (2015) Lucia Mazzacurati et al. Oncotarget
- Ruxolitinib in combination with Lenalidomide as therapy for patients with myelofibrosis
- (2015) N. Daver et al. HAEMATOLOGICA
- A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
- (2015) A. M. Vannucchi et al. HAEMATOLOGICA
- Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
- (2015) S. Verstovsek et al. HAEMATOLOGICA
- Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
- (2015) Animesh Pardanani et al. JAMA Oncology
- JAK2V617F Drives Mcl-1 Expression and Sensitizes Hematologic Cell Lines to Dual Inhibition of JAK2 and Bcl-xL
- (2015) Jun Guo et al. PLoS One
- Combination of PIM and JAK2 inhibitors synergistically suppresses cell proliferation and overcomes drug resistance of myeloproliferative neoplasms
- (2015) Shih-Min A. Huang et al. Oncotarget
- Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors
- (2014) Stuart W. J. Ember et al. ACS Chemical Biology
- Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms
- (2014) Neha Bhagwat et al. BLOOD
- Lysine-specific demethylase 1 (LSD1) in hematopoietic and lymphoid neoplasms
- (2014) D. Niebel et al. BLOOD
- Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
- (2014) R. Rampal et al. BLOOD
- Combination therapy with ruxolitinib plus 5-azacytidine or continuous infusion of low dose cytarabine is feasible in patients with blast-phase myeloproliferative neoplasms
- (2014) Anne Mwirigi et al. BRITISH JOURNAL OF HAEMATOLOGY
- New and emerging HDAC inhibitors for cancer treatment
- (2014) Alison C. West et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies
- (2014) Raoul Tibes et al. Journal of Hematology & Oncology
- Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
- (2014) Pietro Ciceri et al. Nature Chemical Biology
- Targeting bromodomains: epigenetic readers of lysine acetylation
- (2014) Panagis Filippakopoulos et al. NATURE REVIEWS DRUG DISCOVERY
- Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms
- (2014) Raajit Rampal et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis
- (2014) P. S. Winter et al. Science Signaling
- The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms
- (2013) T. Tadmor et al. AMERICAN JOURNAL OF HEMATOLOGY
- Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
- (2013) A. Tefferi et al. BLOOD
- Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon- in a murine model of polycythemia vera
- (2013) A. Mullally et al. BLOOD
- JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFN
- (2013) S. Hasan et al. BLOOD
- The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis
- (2013) Srdan Verstovsek et al. BRITISH JOURNAL OF HAEMATOLOGY
- JAK1/2 and Pan-Deacetylase Inhibitor Combination Therapy Yields Improved Efficacy in Preclinical Mouse Models of JAK2V617F-Driven Disease
- (2013) E. Evrot et al. CLINICAL CANCER RESEARCH
- Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms
- (2013) Niccolò Bartalucci et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- AKT is a therapeutic target in myeloproliferative neoplasms
- (2013) I Khan et al. LEUKEMIA
- BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms
- (2013) B S Wyspiańska et al. LEUKEMIA
- Dual PI3K/AKT/mTOR Inhibitor BEZ235 Synergistically Enhances the Activity of JAK2 Inhibitor against Cultured and Primary Human Myeloproliferative Neoplasm Cells
- (2013) W. Fiskus et al. MOLECULAR CANCER THERAPEUTICS
- mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms
- (2013) Costanza Bogani et al. PLoS One
- Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors
- (2013) Michaela Waibel et al. Cell Reports
- Histone demethylase Lsd1 represses hematopoietic stem and progenitor cell signatures during blood cell maturation
- (2013) Marc A Kerenyi et al. eLife
- Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon- 2a specifically targets JAK2V617F-positive polycythemia vera cells
- (2012) M. Lu et al. BLOOD
- Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia
- (2012) A. Eghtedar et al. BLOOD
- Efficacy of vorinostat in a murine model of polycythemia vera
- (2012) H. Akada et al. BLOOD
- The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem Cells
- (2012) William J. Harris et al. CANCER CELL
- Identification of Regulators of Polyploidization Presents Therapeutic Targets for Treatment of AMKL
- (2012) Qiang Wen et al. CELL
- Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation
- (2012) A Sprüssel et al. LEUKEMIA
- Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
- (2012) Priya Koppikar et al. NATURE
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- TNF facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms
- (2011) A. G. Fleischman et al. BLOOD
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- Heat Shock Protein 90 Inhibitor Is Synergistic with JAK2 Inhibitor and Overcomes Resistance to JAK2-TKI in Human Myeloproliferative Neoplasm Cells
- (2011) W. Fiskus et al. CLINICAL CANCER RESEARCH
- Control of Megakaryocyte Expansion and Bone Marrow Fibrosis by Lysyl Oxidase
- (2011) Alexia Eliades et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
- (2011) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- JAK2V617F negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms
- (2011) M Nakatake et al. ONCOGENE
- Multifaceted Intervention by the Hsp90 Inhibitor Ganetespib (STA-9090) in Cancer Cells with Activated JAK/STAT Signaling
- (2011) David A. Proia et al. PLoS One
- Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903
- (2010) R. A. Mesa et al. BLOOD
- MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF- B-dependent lymphoma
- (2010) M. A. Milhollen et al. BLOOD
- Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia
- (2010) R. T. Swords et al. BLOOD
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
- (2010) A. Quintas-Cardama et al. BLOOD
- Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells
- (2010) Ann Mullally et al. CANCER CELL
- HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans
- (2010) Sachie Marubayashi et al. JOURNAL OF CLINICAL INVESTIGATION
- A phase-2 trial of low-dose pomalidomide in myelofibrosis
- (2010) K H Begna et al. LEUKEMIA
- Therapeutic options for patients with myelofibrosis in blast phase
- (2010) John Mascarenhas et al. LEUKEMIA RESEARCH
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase1/-2 study of Pomalidomide in myelofibrosis
- (2009) Ruben A. Mesa et al. AMERICAN JOURNAL OF HEMATOLOGY
- Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells
- (2009) Y. Wang et al. BLOOD
- Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis
- (2009) Alfonso Quintás-Cardama et al. JOURNAL OF CLINICAL ONCOLOGY
- Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis
- (2009) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
- (2009) Teresa A. Soucy et al. NATURE
- The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms
- (2008) C. S. Tam et al. BLOOD
- The many roles of histone deacetylases in development and physiology: implications for disease and therapy
- (2008) Michael Haberland et al. NATURE REVIEWS GENETICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started